Why the study?
Does K-134 prevent brain damage and inhibit thrombus formation better than cilostazol in a rat cerebral infarction model?
Does K-134 prevent brain damage and inhibit thrombus formation better than cilostazol in a rat cerebral infarction model?
K-134, a potent PDE3 inhibitor, demonstrates superior antithrombotic effects and reduction in cerebral infarct size compared to cilostazol in rat models.
K-134 merits further preclinical optimization; leaves open translation to human cerebral infarction prevention.
No takes yet. Share an insight, caveat, or question.
Yoshida et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: